



Precision BioSciences to Report First Quarter 2021 Financial Results on May 13, 2021

May 6, 2021 at 7:00 AM EDT

DURHAM, N.C.--(BUSINESS WIRE)--May 6, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and *in vivo* gene correction therapies with its ARCUS[®] genome editing platform, today announced it will publish first quarter 2021 financial results and provide a business update on Thursday, May 13, 2021.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS[®] genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several *in vivo* gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.



View source version on [businesswire.com](https://www.businesswire.com/news/home/20210506005331/en/): <https://www.businesswire.com/news/home/20210506005331/en/>

Investor Contact:

Alex Kelly
Interim Chief Financial Officer
Alex.Kelly@precisionbiosciences.com

Media Contact:

Maurissa Messier
Senior Director, Corporate Communications
Maurissa.Messier@precisionbiosciences.com

Source: Precision BioSciences, Inc.